At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 75 enrolled
Drug / intervention
Raltegravir +4 moredrug
Likely dose
Raltegravir 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomised Double-blind Placebo Controlled Study to Measure the Effect of Antiretroviral Therapy (ART) Intensification With Raltegravir and/or Hyper-immune Bovine Colostrum on CD4+ T Cell Count in ART Treated, HIV-1 Infected Individuals With Suboptimal CD4+ T Cell Responses
In Brief
A Phase 4 clinical trial evaluating Raltegravir, Hyper-immune Bovine Colostrum, and 3 other interventions for HIV Infections. Completed, enrolled 75 participants.
Detailed Summary
A research study to measure the effect on CD4 counts of adding to current anti-retroviral regimen raltegravir with or without hyper-immune bovine colostrum.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2008
Enrollment StartMar 2009
Primary CompletionMar 2010
Study CompletionJun 2011
TodayJul 2026
First PostedOct 15, 2008
Enrollment StartMar 1, 2009
Primary CompletionMar 1, 2010
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.7 years ago
Interventions
Raltegravirdrug
Tablets, 400mg, twice daily
Hyper-immune Bovine Colostrumdrug
Tablet, 1800mg, twice daily
raltegravir placeboother
One tablet, twice daily
Hyper-immune Bovine Colostrum placeboother
Three tablets twice daily
raltegravir and hyper-immune bovine colostrumdrug
400mg twice daily raltegravir and 1800mg twice daily of hyper-immune bovine colostrum